Abstract | STUDY DESIGN: Experimental study. OBJECTIVES: SETTING: Department of Neurosurgery, the Second Affiliated Hospital, Xi'an Jiaotong University School of Medcine, Xi'an, Shaanxi Province, China: METHODS: Sprague-Dawley Rats were randomly divided into two groups, saline (IRS, n=48) and Bosentan (IRB, n=48) treatment, respectively, when reperfused in 6 h, 12 h, 24 h, 3 days, 5 days and 7 days. Immunohistochemical staining was used to assess endothelin-1 (ET-1), endothelin receptor type A (ETRA), endothelin receptor type B (ETRB), Bcl-2, Bax, Caspase-8, Caspase-9 and Caspase-3 expression. ET-1 and its receptor in spinal cord tissue were evaluated by real-time PCR. Plasma ET-1 concentration was also detected using radioimmunoassay. RESULTS: Compared with the group IRS, plasma concentration of ET-1 in group IRB was significantly increased at each time point (P<0.05) and peaked at 24 h (P<0.01). ETRB expression in group IRB was significantly higher than group IRS at each time point (P<0.05) and peaked at day 3 (P<0.01). The difference in the expression of ETRA was not statistically significant in the group IRS and IRB (P>0.05). The apoptosis rate in group IRB was significantly decreased at each time point (P<0.05). The protein expressions of Bcl-2, Bax, Caspase-8, Caspase-9 and Caspase-3 were significantly increased in response to Bosentan treatment after IR. CONCLUSION: These results suggest Bosentan decreases apoptosis rate after IR injury in the spinal cord, possibly through the ET-1-ETRB signaling pathway.
|
Authors | S Gong, L Peng, B Yan, Q Dong, Z Seng, W Wang, J Lv, X He |
Journal | Spinal cord
(Spinal Cord)
Vol. 52
Issue 3
Pg. 181-5
(Mar 2014)
ISSN: 1476-5624 [Electronic] England |
PMID | 24276417
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Animals
- Apoptosis
(drug effects)
- Bosentan
- Brain Ischemia
(drug therapy)
- Disease Models, Animal
- Male
- Rats
- Rats, Sprague-Dawley
- Reperfusion Injury
- Spinal Cord
(metabolism)
- Spinal Cord Injuries
(drug therapy, metabolism, pathology)
- Sulfonamides
(administration & dosage, pharmacology)
|